Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Busulfan liposomal - Calliditas Therapeutics

Drug Profile

Busulfan liposomal - Calliditas Therapeutics

Alternative Names: Busulipo; MZH-2

Latest Information Update: 30 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karolinska Institute
  • Developer Calliditas Therapeutics
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone marrow transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone marrow transplant rejection

Most Recent Events

  • 24 Sep 2020 No development reported - Phase-II for Bone marrow transplant rejection (Prevention) in Sweden (IV) (Calliditas Therapeutics website, September 2020)
  • 04 Jan 2012 Pharmalink completes phase II trials in Cancer as a myeloablative agent in Sweden
  • 14 Apr 2008 Phase-II clinical trials in Bone marrow transplant rejection (Prevention) in Sweden (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top